Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | SCN1A | P35498 | 2/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756435 | 0.83 | L3MBTL1 (0.44) | KDM4E | |
| SCHEMBL14247727 | 0.83 | L3MBTL1 (0.44) | KDM4E | |
| SCHEMBL14247790 | 0.83 | L3MBTL1 (0.44) | KDM4E | |
| Hydrochloric Acid SCHEMBL11228436 | 0.83 | KDM4E (0.50) | KDM4EKDM4CLRRK2SCN1ASCN5A | |
| SCHEMBL30894541 | 0.81 | KDM4E (0.62) | KDM4EKDM4CLRRK2SCN1ASCN5A | |
| SCHEMBL16042186 | 0.79 | ALDH1A1 (0.47) | KDM4E | |
| Hydrochloric Acid SCHEMBL11568531 | 0.75 | KDM4E (0.50) | KDM4EKDM4CLRRK2SCN1ASCN5A | |
| SCHEMBL24450229 | 0.73 | KDM4E (0.63) | KDM4ELRRK2VNN1PFKFB3 | |
| SCHEMBL22191343 | 0.73 | KMT2A (0.46) | KDM4ECYP11B1CYP11B2 | |
| SCHEMBL8200994 | 0.72 | HDAC1 (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650358-B2 | Pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2970200-A1 | PYRIDINE CDK9 KINASE INHIBITORS | Abbvie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160017-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275011-A1 | PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK6 | KDM4E 340/4885KDM4C 539/4885LRRK2 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.